Capital Fund Management S.A. Sage Therapeutics, Inc. Call Options Transaction History

Capital Fund Management S.A.

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $778,316 - $1.13 Million	-41,800 Reduced 56.11%	32,700 $612,000
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $713,070 - $928,242	41,700 Added 127.13%	74,500 $1.61 Million
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $549,400 - $1.61 Million	32,800 New	32,800 $675,000
Q3 2020 Nov 13, 2020	SELL	$41.13 - $62.45 $563,481 - $855,565	-13,700 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$25.95 - $43.15 $355,515 - $591,155	13,700 New	13,700 $569,000
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $317,653 - $388,792	-2,300 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $322,828 - $404,248	2,300 New	2,300 $360,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.